Lioness Associates, Inc.

Economic & Corporate Risk/Yield Reports

November 18, 2012  -- Onyx Pharmaceuticals Update Risk/Yield for 2012

Refer to Reading Graphs for information on interpretation of the graphs.

As noted in the earlier post of June 22, 2012, there were astrological configurations that indicated momentum for a positive result from the FDA process in July which eventually did turn out to be positive. The gains that the company's stock price has had since then have started to be given back during the down momentum of the general market over the last few weeks.

Moving forward — nothing obvious in the configurations for the rest of the 2012 year that would spark a decided move into either risk or yield.  Although, there is some movement into yield for the December 2012 period for both core and yield but, whatever conclusion there is to this particular move is in the 2013 year and is not shown in the 2012 graphs.

Note, there is a potential of takeover rumors starting again in January of 2013 — whether they are based in fact or fiction is hard to decipher presently. This topic will be re-addressed in a few weeks.


June 22, 2012  -- Onyx Pharmaceuticals Risk/Yield for 2012

More Upside?

Onyx Pharmaceuticals
received news on 6/20/2012 that the "FDA panel backs Kyprolis for treatment of multiple myeloma".  Shortly before the news, trading was stopped on the stock and did not continue until the next day, 6/21/2012.  Before being stopped, the stock was trading at $44.51 and opened the next day at $61.36 - a significant increase.  The next action by the FDA is expected on 7/27/2012 (see article).

The ONXX Delta Core/Transient 2012 graph does depict the rise in momentum into yield from the beginning of April to approximately mid-April of 2012.  While the momentum decreases from May to July, it does not drop into the Risk area. 

Looking at the ONXX Risk/Yield 2012 graph, both the April and June 2012 periods had significant Yield factors with the only difference being  - the June period had more "Risk" factors. 

The astrological data does have some positive indications near the beginning of August 2012 which could correlate with the FDA decision. But, a positive FDA decision may already be in the included in the current price of the stock - hard to tell. 

There were a few rumors back in April of 2012 about a possible takeover of this company - some astrological indications are signaling that this might start up again near the end of this year or the beginning of next year.  It could be that interested parties start "sniffing the skirts" of this company as early as September of this year. 


       ONXX Delta Core/Transient 2012 graph

         ONXX Risk/Yield 2012 graph

Disclosure as of 6/22/2012 - Onyx Pharmaceuticals (ONXX) is not part of our portfolio at this time.